Bone Biologics Corp develops orthobiologic products for spine fusion markets, with its work centered on bone regeneration using the recombinant human protein rhNELL-1. Its lead product candidate, NB1, combines rhNELL-1 with demineralized bone matrix and is tied to the company’s focus on targeted bone regeneration in spinal fusion, with rights also noted for trauma and osteoporosis applications.
News about BBLG commonly covers clinical-development progress, product-readiness milestones such as rhNELL-1 shelf-life validation, patent activity, financing transactions, Nasdaq listing compliance, and corporate updates on scientific and operational priorities.
Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, has successfully closed its previously announced $5.0 million public offering. The offering consisted of 1,250,000 shares of common stock (or equivalents) and two series of warrants at a public offering price of $4.00 per share.
The offering includes Series D warrants with a 5-year term and Series E short-term warrants with an 18-month term, both with an exercise price of $4.00 per share. If fully exercised, these warrants could provide additional gross proceeds of $10.0 million. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
The company plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.
Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, has announced the pricing of a $5.0 million public offering. The offering consists of 1,250,000 shares of common stock (or equivalents) at $4.00 per share, along with Series D and Series E warrants.
The offering includes Series D warrants with a 5-year term and Series E short-term warrants with an 18-month term, both with an exercise price of $4.00 per share. If fully exercised, the warrants could provide additional gross proceeds of $10.0 million. The company plans to use the proceeds for clinical trials, patent portfolio maintenance, and working capital.
Bone Biologics (NASDAQ: BBLG) has filed a patent application with the USPTO for its novel NELL-1 protein technology. The application covers compositions of rhNELL-1 polypeptide and its applications in treating bone conditions.
The patent filing represents a significant milestone for the company's intellectual property portfolio and supports their clinical development program in spine fusion treatments.
Bone Biologics (NASDAQ:BBLG), a developer of orthobiologic products for spine fusion markets, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq that it has met the listing requirement of maintaining a closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving this milestone on June 24, 2025.
This development resolves the non-compliance notice issued on April 7, 2025, and ensures BBLG's continued listing on the Nasdaq Capital Market. The company is now in full compliance with all applicable Nasdaq listing standards.
Bone Biologics (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, has appointed Phillip T. Meikle to its Board of Directors. Mr. Meikle brings over 30 years of commercial experience in the orthopedic and spine industry. He succeeds Don R. Hankey, who retired after seven years of service. The board remains at four directors.
Mr. Meikle was previously the president and CEO of Biosystems of New England, Inc., an orthopedic distribution company he founded in 1992 and sold to Stryker in 2019. He has been a consultant to Stryker Spine for the past five years. His company served as a distributor for Stryker Spine from 2002 to 2019 and for Medtronic Spine from 1992 to 2002.
Jeffrey Frelick, president and CEO of Bone Biologics, expressed enthusiasm about Mr. Meikle's appointment, citing his extensive experience with orthopedic and spine products as particularly valuable as the company develops NB1 for spinal fusion patients.
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Jeffrey Frelick, the company's CEO, will deliver a virtual presentation, which will be accessible online starting September 9th at 7:00 a.m. Eastern time.
The presentation will remain available on the company's website for a time. Bone Biologics' management team will also be available for virtual one-on-one meetings throughout the conference. Institutional investors and industry professionals can choose to attend the conference either virtually or in-person at the Lotte New York Palace Hotel.
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced a $2.1 million gross proceeds from the exercise of warrants. The company entered into a definitive agreement for the exercise of existing warrants to purchase 781,251 shares of common stock at $2.43 per share. In exchange, Bone Biologics will issue new unregistered warrants to purchase up to 1,562,502 shares of common stock at $2.00 per share.
The new warrants will have varying terms: half with a five-year term and half with an eighteen-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around August 2, 2024. Bone Biologics plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.
Bone Biologics (Nasdaq: BBLG) has commenced the first treatments in its pilot clinical study evaluating the NB1 bone graft device for spine fusion in patients with degenerative disc disease (DDD). The study, involving 30 patients, aims to assess the safety, effectiveness, fusion success, pain relief, functional improvement, and adverse events of NB1. The first two patients were treated in Australia. The U.S. FDA has reviewed and agreed upon the study's design, which could support a pivotal U.S. trial. CEO Jeffrey Frelick highlighted NB1's potential to address a $3 billion global spine fusion market.
Summary not available.